Caribou Biosciences Reports Third Quarter 2022 Financial Results and Provides Business Update
-- CB-010 ANTLER Phase 1 trial in r/r B-NHL advancing; additional data from cohort 1 expected by YE 2022 -- -- CB-011 IND application for r/r MM submitted to FDA in Q4 2022 -- -- Strong financial position of $342.6 million in cash, cash equivalents, and …